Investing3d
Roivant at Leerink’s Conference: Strategic Insights and Developments
Matt Klein, CEO, Royvant: That is perhaps the most polite way anyone has described the current sentiment amount of ImmunoVent Dave: to me. So I appreciate Matt Klein, CEO, Royvant: that.
Investing3d
Roivant at Leerink’s Conference: Strategic Insights and Developments
Matt Klein, CEO, Royvant: That is perhaps the most polite way anyone has described the current sentiment amount of ImmunoVent Dave: to me. So I appreciate Matt Klein, CEO, Royvant: that. Yes, look, so ...
pharmaphorum8d
UK grants early access to Argenx' efgartigimod for myasthenia gravis
UCB has a subcutaneous FcRn drug – rozanolixizumab – which cleared a phase 3 trial last year, while other drugs in the class from Johnson & Johnson/Momenta (nipocalimab) and ImmunoVent ...